A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

A computerized clinical decision support tool implemented as a diagnostic stewardship intervention led to an approximate 50% decrease in urine culture testing for patients with a urinary catheter, ...

Patients with POD24 had a complete response rate of 77%. The most common adverse events in the follicular lymphoma trial were ...

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...

One patient in the 12-week 180 mg group developed unrelated neutropenia, and one in the placebo group developed bronchitis. Events possibly related to the c-Kit blockade included four patients in the ...

TRAEs of any grade that were more common in the chemotherapy arm than in the nivolumab-ipilimumab arm included diarrhea (51% and 21%), asthenia (35% and 14%), fatigue (14% and 13%), nausea (47% and 5% ...

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th- National Comprehensive Cancer ...

In the PTCL and adult T-cell leukemia/lymphoma groups, the most common grade 3 or 4 adverse events were thrombocytopenia (23% and 50%, respectively), anemia (19% and 46%), and neutropenia (17% and 18% ...

The combination of talquetamab and teclistamab “warrants further investigation in patients with relapsed or refractory multiple myeloma,” according to researchers.

Cancer treatments, especially chemotherapy and radiation, cause significant damage to the body’s blood cells. While these ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...